#### INTENDED USE

The **Human Anti-Herceptin/trastuzumab** or anti-drug antibodies (HADA) ELISA Kit is an immunoassay suitable for detecting and quantifying human antibody activity against **Herceptin/Trastuzumab** of any isotype, in human serum or plasma. It is validated for human sample but it should work in other species as well. This kit is for research use only.

#### **GENERAL INFORMATION**

HER2 (Human Epidermal Growth Factor Receptor 2/New/Erbb2) is over-expressed in ~30% of breast cancers. Herceptin, a fully humanized monoclonal antibody (IgG1k) that neutralized Her2 and used to treat some breast cancer patients. Humanized antibodies are 'Animal Antibodies' that have been engineered by recombinant DNA-technology to reduce the overall content of the animal-portion of IgG so as to increase acceptance by humans or minimize 'rejection'. The portion of the mouse IgG that remains in the 'humanized IgG' or even the human portion may be recognized as foreign by humans and may result into the generation of "Human Anti-Drug Antibodies (HADA or Human Anti-Mouse Antibodies or HAMA). Some patients receiving Herceptin developed some form of anti-Herceptin (HADA) response. The presence of anti-Drug antibody (e.g., Human Anti-Herceptin IgG) may limit the long-term usage the humanized antibody (Herceptin). The prevalence of anti-drug antibodies are highly dependent upon the nature of sample, duration of therapy, and sensitivity of the assay. Therefore it is necessary to monitor the presence of anti-Herceptin antibody levels in patients receiving long-term Herceptin immunotherapy.

#### PRINCIPLE OF THE TEST

The Human Anti-Herceptin IgG ELISA kit is a double antigen sandwich ELISA based on the binding of anti-Herceptin antibodies (any isotype) in samples to Herceptin immobilized on the microwells; bound anti-Herceptin Ig's are detected by simultaneously binding to Herceptin-HRP (horseradish peroxidase) enzyme, forming a sandwich. After a washing step, chromogenic substrate (TMB) is added and color (blue) is developed, which is directly proportional to the amount of antibody present in the sample. Stopping Solution is added to terminate the reaction (converts blue color to yellow), and A450nm (yellow color) is measured using an ELISA reader. The presence of anti-Herceptin antibody in samples is determined relative to controls.

#### PRODUCT SPECIFICATIONS

#### Specificity

Purified Herceptin is used to coat the microwells and detected by Herceptin-HRP; thus the assay is specific for antibodies directed to Herceptin and not simply detect common human-anti-human Ig's (HAHA). It is possible that some samples may have common HAHA but not antibodies specific to Herceptin. The Herceptin-HRP conjugate reacts with divalent or multivalent antibodies of either isotype (IgG, IgM, IgA, IgE). The assay, however, will not distinguish between antibodies made to the mouse or human portions of Herceptin. This kit should detect antibodies to Herceptin in any species.

#### **Assay Sensitivity**

The Herceptin antigen coating level and Herceptin-HRP conjugate concentration are optimized to differentiate anti-Herceptin IgG from background (non-antibody) signal with human serum samples diluted 1:20 or higher.

#### KIT CONTENTS

The microtiter well plate and all other reagents, if unopened, are stable at 2-8<sup>o</sup>C until the expiration date printed on the box label. Stabilities of the working solutions are indicated under Reagent Preparation.

To Be Reconstituted: Store as indicated.

Component	Preparation Instructions
Wash Solution Concentrate (100x) Cat. No. WB-100, 10ml	Dilute the entire volume 10ml + 990ml with distilled or deionized water into a clean stock bottle. Label as <b>Working Wash Solution</b> and store at ambient temperature until kit is used entirely.
Sample Diluent Concentrate (20x) Cat. No. SD-20T, 10ml	Dilute the entire volume, 10ml + 190ml with distilled or deionized water into a clean stock bottle. Label as <b>Working Sample Diluent</b> and store at 2-8°C until the kit lot expires or is used up.
Herceptin - HRP Conjugate Concentrate (100x) Part: 200-323, 0.15ml	Peroxidase conjugated mouse IgG in buffer with detergents and antimicrobial as stabilizers. Dilute fresh as needed; 10ul of concentrate to 1ml of <b>Working Sample Diluent</b> is sufficient for 1 8-well strip. Use within the working day and discard. Return 100X to 2-8° C storage.

Ready For Use: Store as indicated on labels.

Component	Part	Amt	Contents
Herceptin IgG Microwell Strip Plate	200-521	8-well strips (12)	Coated with mouse IgG antigen, and post-coated with stabilizers.
Anti-Heceptin IgG Calibrators			
5 U/ml 10 U/ml 20 U/ml 40 U/ml	200-522B 200-522C 200-522D 200-522E	0.65 ml 0.65 ml 0.65 ml 0.65 ml	Four (4) vials, each containing human anti-rituximan IgG; in buffer with protein, detergents and antimicrobial as stabilizers.
TMB Substrate	80091	12 ml	Chromogenic substrate for HRP containing TMB and peroxide.
Stop Solution	80101	12 ml	Dilute sulfuric acid.

## Materials Required But Not Provided:

- Pipettors and pipettes that deliver 100ul and 1-10ml. A multi-channel pipettor is recommended.
- Disposable glass or plastic 5-15ml tubes for diluting samples and IgG HRP Concentrate.
- Graduated cylinder to dilute Wash Concentrate; 0.2 to 1L.
- Stock bottle to store diluted Wash Solution: 0.2 to 1L.
- Distilled or deionized water to dilute reagent concentrates.
- Microwell plate reader at 450 nm wavelength.

#### LIMITATIONS OF THE ASSAY

#### Quantitation of Antibody in a Sample

The ELISA measures anti-Herceptin IgG activity, a combination of antibody concentration and avidity for the Herceptin antigens. Antibodies with substantially different total Ig's concentrations may display similar anti-Herceptin IgG activities, due to differences in avidity. The quantitation or activity of the samples is, therefore, appropriately expressed in activity Units (titer), rather than mass units of Ig (e.g., ug/ml).

## **ASSAY DESIGN AND SET-UP**

#### Sample Collection and Handling

Serum and other biological fluids may be used as samples with proper dilution to avoid solution matrix interference. For serum, collect blood by venipuncture, allow clotting, and separate the serum by centrifugation at room temperature. For other samples, clarify the sample by centrifugation and/or filtration prior to dilution in Sample Diluent. If samples will not be assayed immediately, store refrigerated for up to a few weeks, or frozen for long-term storage. We recommend an initial testing of samples at 1:20 dilutions and if the background remains <0.300 then samples can be tested at 1:10-1:20 dilution.

#### **Antibody Stability**

Initial dilution of serum into **Working Sample Diluent** (WSD) is recommended to stabilize antibody activity. This enhances reproducible sampling, and stabilizes the antibody activity for years, stored refrigerated or frozen.

#### **Assay Design**

Review Calculation of Results (p5-7) and Limits of the Assay (above) before proceeding:

- Select the proper sample dilutions accounting for expected potency of positives and minimizing non-specific binding (NSB) and other matrix effects; for example, net signal for non-immune samples should be lower than the 5 U/mI Calibrator. This is usually 1/50 dilution or greater dilution for human sera with normal levels of IqG and IdM.
- Run a Sample Diluent Blank. This signal is an indicator of proper assay performance, especially of washing efficacy, and is used for net OD calculations, if required. Blank OD should be <0.3.</li>
- Run a set of Calibrators. Calibrators validate that the assay
  was performed to specifications; results can be used to
  normalize between-assay variation for enhanced precision.
  Reading values off a Calibrator curve, Method A, has
  limitations. See Limits of the Assay (above).

## Plate Set-up

Bring all reagents to room temperature (18-30° C) equilibration (at least 30 minutes).

- Determine the number of wells for the assay run.
   Duplicates are recommended, including 8 Calibrator wells and 2 wells for each sample and internal control to be assayed.
- Remove the appropriate number of microwell strips from the pouch and return unused strips to the pouch. Reseal the pouch and store refrigerated.

#### **ASSAY DESIGN AND SET-UP (continued)**

 Add 200-300ul Working Wash Solution to each well and let stand for about 5 minutes. Aspirate or dump the liquid and pat dry on a paper towel before sample addition.

#### **Assav Procedure**

ALL STEPS ARE PERFORMED AT ROOM TEMPERATURE. After each reagent addition, gently tap the plate to mix the well contents prior to beginning incubation.

#### 1. 1st Incubation [100ul – 60 min; 4 washes]

- Add 100ul of calibrators, samples and controls each to predetermined wells
- Tap the plate gently to mix reagents and incubate for 60 minutes.
- Wash wells 4 times and pat dry on fresh paper towels. As an alternative, an automatic plate washer may be used. Improper washes may lead to falsely elevated signals and poor reproducibility.

## 2. 2<sup>nd</sup> Incubation [100ul – 30 min; 5 washes]

- Add 100ul of diluted Rituximab-HRP to each well.
- Incubate for 30 minutes.
- Wash wells 5 times as in step 2.

### 3. Substrate Incubation

[100ul - 15 min]

- Add 100ul TMB Substrate to each well. The liquid in the wells will begin to turn blue.
- Incubate for 15 minutes in the dark, e.g., place in a drawer or closet.

Note: If your microplate reader does not register optical density (OD) above 2.0, incubate for less time, or read OD at 405-410 nm (results are valid).

#### 4. Stop Step [Stop: 100ul]

- Add 100ul of Stop Solution to each well.
- Tap gently to mix. The enzyme reaction will stop; liquid in the wells will turn yellow.

#### 5. Absorbance Reading

- Use any commercially available microplate reader capable of reading at 450nm wavelength. Use a program suitable for obtaining OD readings, and data calculations if available.
- Read absorbance of the entire plate at 450nm using a single wavelength within 30 minutes after Stop Solution addition. If available, program to subtract OD at 630nm to normalize well background.

Page 1 Page 2 Page 3 Page 4

## INTERPRETATION OF RESULTS

#### Calculation of Results

Ô[}•ãā^¦Á•^ç^|æqÁåæææÁ^å°&āā¸}Á(^o@\_å•Áq́Áà^•óÁ^)¦^•^}oó@^Á ¦^|ææā¸}•@ā•Áæ{[}\*Á^¢]^¦ā{^}æáÁæa¸àÁ&{}d[|Á\*¦[°]•ÉAqíÁ å^c^¦{ā}^ÁPositive ImmuneÁæ)åÁNegative Non-immune[¦ÁPreimmuneÉæ)åÁşÁQuantitateÁ;[•ãæî;^Áæ)cãa[â^Á;ç^|•ÉÁ

#### Method A. Use of a Calibrator Curve


Y @ } ho@ haā' cā; } ks`; ç^• h; A; æ; ] | ^• hæ'^ A; æ; æi|^ | hiệ ha@ hôæjāi æi ; h &`; ç^ hāp^^ hāā; āo h; A; h@ hoë • æi hā; æ ^ A; hāba; āhi/• \* | o hā; æ ^ A; hāba@ h æ; cāt [ \*•^ hāē hæ; cā; āc h]; āo h; æ hā^ hā^ ch; ch; { aj^ à ha` hā ch; ] [ | ææā; } h - [ { ha@ hôæjāi æi; !ks`; ç^ bāh

Sample values  $M^{k}$   $c^{\hat{A}}$   $c^{\hat{A}}$ 

## Method B. Antibody Activity Threshold Index

Ô[{]æ^ÂĴæ{]|^•Á[Á10 U/ml CalibratorÁ¦Ánternal Control =ÁPositive/Negative Cut-offÉÁ

## Example:



OB; caEP^\8^] caj ÁClen ÁÚcan á sa á ÁÓ ¹; ç^ÁÇA[Á] (Á • ^Ás@á Á[Á A æ [] |^Á 8æ48² |æa [} • DÁD cnoossan

## Results

\`@ ÁsensitivityÁ; Ác@ Áœ • æ Áṭ Áå^ ৫ & Aóæ à æ ÊP^\&\] caj Ácī ÕĒĀ-[{ Á
^ā@\Á}æ ¡æ ¡æ Áv¢][• ` ¡^Á[ ¡Áå|` \* Áœå { āj ā dæaā } ĒĀā ÁS[ } d[ ]|^å Á•[ Á
c@æ Áœ Á5 U/ml CalibratorÁ^] ¦^•^} o Áæ Áœ 4@ ] å ÁUÖÁţ ¦ Á; [• cá
d`^Á][•āāā,^•Áāj Á@ { æ) Á•^!` { Áāā c° å Áāj Ác@ ÁÙæ { ] |^ÁÖā ^}} o Áææ Á
FK €Ā; Á¹ |^æ \* ¡ĒÁ

FÁ } ā/ḥ , -Áæḥ ; cāĒP^l & ^] cā jÁ roca) å cab å \* MFÁ; \* 10 | Jḥ , -Ác@ Á [ | \* & | } cab Å \* ^ å Á
ā Á coga Á là ābÁÁU cog lÁca) caĒP^l & ^] cā jÁ [ lÁca) caĒc { cab Á Q.Õ Áca jca là að \* Á
{ cab Á / ^ cab coáa Ãca l^ } } q \* Áca) å Áj ! [ å \* & ^ Á å Ãca l^ } ) chaos cap āc Ágā jà āj \* Áq Á
@ { cab ÁQ Õ Doba) å Æ [ } & ^ } desa j jÁc | ç ^ • ÉÁ

V@Á5 U/ml CalibratorÁ&a)Áà^Á\*•^åÁqíÁ&a;&;|æc^ÁæÁThreshold Index c@æÁ}\*{^¦ä&a;|^Áåã\*&¦ã;ā;æc^•ÁÚ[•ããā;^Bo^\*æsã;^ÉÁæ•Á -[;||[,•KÁ

^ V@sÁ&æk&: |æaई|}Áæt|[ÁquantifiesÁc@Á][•áāā;^ÁCB;cāa[á^ÁCB&aā;ā:Á |^ç^|Éæe•ā}ā;ā\*Áæk@ā@!Á;æ;\*^ÁṭÁ•æṭ]|^•Á;āœA@ā@!ÁCB;cāa[á^Á CB&ā;ā:Éæs)áÁ;ā&Aç^{\*}•æÉA

## **ASSAY PERFORMANCE**

#### **Detection Range and Specificity**

V @ā Áæ• æ ÉÁæ• Á, ão@Áæ|Á[o@¦Áæ• æ • Ác@æóÁ{ ^æ• ¦^Áæ} oãa[â^Á æ&oãaã ÉÁ;[å\* &^• kÁ

ÁnadÁäā^\^}ó4•ā\*}æpÁ|^ç^|•Á¸ão@Á^~~ãpæp^}óÁæ;[~}o•Á[-Á^æ&@Á æ}œã[å^£Ä¦Á

\(\hat{\text{A}}\) \(\hat{\text{

8DM(@Áçæ;\*^Áṭ!Á@Áæ; œĒP^!&^] σॊ ÁŒ;q Áā Á; æ; ] |^•Áæ;^Áāā^!^} cĀ -![{Áāā^!^},dA^\*ā]•Á; Á@Áœ;à àæà÷Æ;;c^Á Áæ;Á ^æ\* '!^Ā;Ā;Ē] ] ææ;Ā[ā; Áā`^Áṭ Áāā^!^} &^•Áā Áæ;Ā;āæ;Ā; Áæ;Ææ;æā;Ā;ĀœÁæ;æā;āæ;Ā;Āœ,Áæ;iāæ;Ā;Ā;Áæ;Áæ; @{æ;Ā;ŌÁæ;ā\*^}Œ;Y@}Áæ;Ā;&&`!•É;•^Áæ;Áæ;āā^!^};ōṭ^•○@āÁ;!Á ~\*æ;Ā;ææ;ā}Ā;Ē;ĒĒT;^o@āÁo;Ā;IĀDĪĒĀ

#### INTERPRETATION OF RESULTS

#### C. Positive IndexÁ

Öç]^{ā,^}cæţÁaæṭ]|^Áṣæţ^^-Á;æ6Ás^Ár¢]|^^•^åÁr|ææā;^ÁqíÁc@Á ;æţ^^•Á;ÁÖ[}d[|Á;IÁÞ[}Ëā{ {`}^Áæṭ]|^•ĒÁs^Ásæţ&\*|ææā;}Á;ÁæÁ Positive IndexEAU}^Ác]&æq¼;^c@åÆsÁæÁ;{|[;•kÁ

FÉÁ Ôæ¢&`|ææ^Ás@Á,^cÁJÖÁ;^æ}ÆÉÁGÁJÖÁ;Ás@ÁÔ[}d[|Ð⊅[]Ë a[{`}^Á;æ{]|^•ÁMÁPositive IndexÉÁ

GĂ Öãçãa^Áa&@Áæ; ] \^Á,^cÁUÖÁa`Áæ@ÁÚ[•ããç^Ágàà^¢ÞÁæ; ^•Á æà[ç^ÆÈÉÁæ/Áæi; ^æ\*;\^Á,-ÆPositiveÁU;cãa[â\*ÁDBxãçãĉ LÁ à^[[﹑ÆÈÉÁæ/ÁNegativeÁ;!Áæ)cãa[â\*ÉÅ

 C克·森
 [ / Á; 本] / Á; \* / Á; [ \* Jáha / ÁPositive ã Á 君 } ã 器 之 ť Á æ á [ ぐ Á; 全 Á; 本] \* / Á

 [ 左 右] / Č 持 { \* } / Á / A; \* ( Á / A; † Á / A; † Á / A; \* É / Á / A; † É / Á / A; † Á / Á / A; † Á / A;

V@nÁ&e4&; |æaā[}Áea‡•[ÁquantifiesÁc@Á][•āāā;^ÁO5; cāa[ā^ÁO5&cāā;āčÁ |^ç^|Éæe•ā]}ā]\*Áæá@n@¦Áçæ;^Áq[Á•æ{]|^•Á;āoáA@n@¦ÁO5; cāa[ā^Á O5&cā;ācÉāe;àÁṣā&^Áṣ^|•æáA

#### Species Reactivity

## Expected Results

OŞ ÁĞ ËQ\*•^Á; Ğ å^Á; Á; [4; [4 æÁ@ { æ; Á; ^\; { Á; æ; ] | ^• ÁædÁFKGÍ Á; ¦Á FHF€€Áåä; qā; }• ÁåääÁ} [ oÁ^ã\*|åÁçæ; ^• Á\*¦^ææ^¦Áo@æ; Áo@ Á|[¸ ^• óÁ • œa; åædåÁtÁNÐ | LÍDÁ

OB8&[¦åā]\*Án[Á5]-[¦{ææā[}Á-'[{ÁP^¦&^]c3]ÁQÕ^}^}c^&@DDÁ

#### Immunogenicity:

O • Á, ão @ÁællÁc@\ael^`ca&Á|\[c^a] • ÉÁc@\^Áa•ÁæÁ|[c^}caælÁ[\Á ã[{ ` }[ \* ^ } ã&ãĉ ÞÁÁOE[ [ } \* ÁJ€HÁ, [ { ^ } Á, ão@Á( ^ cæ• cæeã&Á à¦^æ•oÁ&æà,&^¦ÉÁ@{æà,Áæa}oäË@{æà,Áæa}oãaí[å^ÁOPOEPOEDÁd;Á  $P^{k}$   $A^{\hat{a}}$   $A^{\hat{a}}$  A] aecāl) oha ān Á, [ohlo] ^ lal) & ^ Áce} Áce} Áce| ^ l\* a& Á ^ ae& cāl} EÁÁ Úae[] | ^ • Á -{ | Áæ••^••{ ^} oÁ| -ÁPOEPOEÁ| ^ | ^Á| | oÁ&| | | ^&c^åÁa| Á•c°åã•Á [-Áæåboçæ) cÁá¦^æ cÁ&æ) &^¦ÉÁÁV@Áã; &ãå^} &^Á[-Áæ) cãa[å^Á •] ^&ãã&ãc Á[ -Ác@ Áæ•æ ÉÁÁŒåããã } æ| ÊÁc@ Á[ à•^¦ç^åÁ ā 8ã ^} 8 ^ Á -Áæ) cã [å ^ÁQ] 8 | å ā \* Á , ^ dæ ā ā \* Áæ) cã [å DÁ ][•ããããã Áã Áæ) Áæ••æ Á{æ Áà^Áã -|`^}&^åÁà^Á•^ç^¦æ Á ~a&c[|•Áā,8| åā,\*Áæ,•æÂ( ^c@ å[|[\*^Ê+æ( ]|^Á@e) å|ā,\*ÊÁ æ) åÁ \*} å^¦|^ã, \*Á åã^æ^ÈÁ Á Ø[¦Á œ••^Á ¦^æ=[}•ÊÁ &[{] æ[a=[}Á[-Ác@ Áa] &aa^} &^Á[-Áæ] caa[a=a-Af ÁP^¦&^] caj Á ão@Ác@ Áð, &ãå^} &^Á; -Áæ) cãà[åðà•Áq Á; c@ ¦Áj ¦[å \* & o•Á(æê Á à^Álãi|^æåãi\*ÈÁ

## PRECAUTIONS AND SAFETY INSTRUCTIONS

# **General References**

P`åā ÁÔŒÁÇŒŒ DÁÞĒÁÒ; \* [ĒÁRĒÁT ^ åĒÁH JĒ ĒLÁŸ ÁÖÁÇŒŒDÁ U} &[\*^}ÁFJĒÁ FFÍĒ FCFLÁS \* «ÁVÁÇŒŒ DÁÔ~ (; { ^d^Á Í ïæÉÀ ÎĒJHÁ Ùæ) qā ÁŒÖÁÇŒĒ DÁQÆĀRĚŐ^} ^ &[ JĒÚa• «ÆÆŒĒÆĞĒ ĒHFLÁÁ @cilhed \_\_\_\_\_ Ē@\&^] qā BĚ( { £@\&^] qā £DææÅ} dā å^¢Ē•] Á ÁÁÁQ,•dˇ&cā[}ÁTæ), ĭæjÁÞ[ÉÁTËЀ€ÉÍG€ÉÐEÞŐÁ

# **ELISA Kit # 200-520-AHG**

For Quantitation of Anti-Herceptin/ Trastuzumab IgBg in Serum or Plasma in Human or other species.



## India Contact:

# Life Technologies (India) Pvt. Ltd.

306, Aggarwal City Mafi, Opposite M2K Pitampura, Delhi – 110034 (INDIA).

Ph: +91-11-42208000, 42208111, 42208222

Mobile: +91-9810521400 Fax: +91-11-42208444

Email: customerservice atzlabs.com
Web: www.atzlabs.com

Á Á ELISA Kit Components

P^\&^] c3 AO[ ae^ åAT a&| [ . ^||AWWW ‱ikä,ë,∧∥Arda]•AMG⊖∈€ÉGFÁ XXXXXQdal AUlase∧AXX QE caEZP ^ & ^ ] ca AQ Õ AÔ ada læg | AMMMMMMM AND | AMMMET Í A | AMMMMMMG∈∈ET GGÓÁ OE da AR O A Cara i and a cara i A A Cara i and a cara i A A A Cara i and a cara i A A A Cara i and a cara i A A A Cara i and a cara i A A A Cara i and a cara i A A A Cara i and a cara i CE cation 80 ca AQ O AO agail agt | AMMMMMMOSAND | AMMSET I A, I AMMMMMOSEET GOO'A P^¦&^] c∄ ÁPÜÚÁÔ[} b \* ææ^ÁŒ€€ÝD₩₩₩₩₩₩₩₩ WWW.EEFÍÀ I/WWWW.GEEEFGHA Ùæ{ ] |^ÁÖã`^} ơŒ€ÝD₩₩₩ WWF€Á IÆWWWÚÜÖG€VÁ XXXXXXF€À IXXXXXXXY ÓËF€€A Yæ• @ÁÛ[| ˈca[} ÁÔ[} &^} dæc^ÁQF€€ÝDÁWWW VT ÓÁU à dæ AM ‱wfgái i‱‱i €€JFÁ WWW.FGÁ I/WWWW.A.€F€FÁ ₩₩FÁYæ₩₩TËD€€Ë G€ËDEPÕÁ

Part

Amount

DRAFT Version-Use the manual supplied with the kit.

₩₩₩₩₩₩₽age 5

####Page 6

.....